Delfina offers a platform for pregnancy organizing patient information, optimizing data workflows for physicians, and using machine learning algorithms to improve predictive capabilities. The software predicts clinically actionable events and recommends timely interventions that will improve patient care by alerting physicians to high-risk patterns in real time. The company was formerly known as Falcon Health and changed its name to Delfina. The company was founded in 2020 and is based in San Francisco, California.
Delfina's Product Videos
ESPs containing Delfina
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The maternal & fetal health screening market is focused on providing high-quality pregnancy care and expanding the standard of care for expectant mothers. Companies in this market diagnose maternal and fetal health conditions, including premature birth risk and fetal oxygenation during labor. These products and services include antenatal screening, genetic testing, ultrasound, and prenatal care. T…
Delfina's Products & Differentiators
Delfina Care is a data-driven, managed care solution offering AI-enhanced personalized care to patients and providers. Delfina Care’s holistic platform includes the Delfina patient facing Pregnancy App, which is integrated with remote monitoring, and provider dashboards that feature personalized patient insights. Delfina Care also offers patients consistent support via check-ins with Delfina Guides . Delfina Care is an integrated pregnancy data platform which utilizes machine learning algorithms to synthesize data from three key sources: patients, electronic medical records, and remote monitoring devices, to provide equitable assessment of pregnancy risks. The Delfina Care platform uses proprietary predictive models to help care teams understand the risk profiles of patients and optimize plans to improve pregnancy outcomes.
Research containing Delfina
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Delfina in 3 CB Insights research briefs, most recently on Nov 11, 2022.
Expert Collections containing Delfina
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Delfina is included in 3 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Women's Health Tech
This collection includes companies applying technology to address a spectrum of physical, mental, and social well-being concerns specific to women. Examples include companies in reproductive health, maternal care, fertility tracking, and menopause support.
Latest Delfina News
Nov 7, 2023
Strike Impact This market was always going to be “light” as one packaging agent described it, due to the strike. Sellers and packagers were hampered by not being able to secure or announce a number of actors for projects. There were a handful of packages that were whispered to buyers but not formally unveiled. Thorsten Ritter of German sales firm Beta told us: “We are facing uncertainty amongst the agents as to what they feel is best for their talent. Having an actor commit at the moment is a difficult thing to accomplish.” Paris-based Gregory Chambet of WTFilms added: “The strike has had an impact on two of our projects which are on standby because we cannot move forward with casting or even detailed discussions with American partners due to the strike.” Despite that challenge, buyers we spoke to were pleasantly surprised by the number of projects that were announced, many with interim agreements or European shooting schedules. The indie sector remains resourceful and resilient. As ever at AFM, sellers leaned into genre fare. Among those projects we heard positive things about were A24’s Civil War and Mother Mary, FilmNation’s Novocaine, Black Bear’s She Rides Shotgun and Wicker, Anton and Charades’ Night Of The Zoopocalypse, and Protagonist’s Spider Island. There were a couple of big-budget options for those with deeper pockets: Lionsgate’s Highlander reboot, which has a budget well north of $100M (prices were eye-watering, with the initial Germany ask reportedly north of $20M), and Kevin Costner’s Horizon: An American Saga, which comprises two $100M movies. As has been the trend the last couple of years, the big-ticket in-market deals are increasingly scarce, even the traditional ‘slew of deals’ stories on big packages. Deals will get tied up (Netflix, Neon, and SPC were among buyers out of TIFF, eventually) but everything takes longer now. Thus, there are the familiar promises of “a Big Berlin”. Arclight’s Brian Beckman predicts: “I think Berlin is in a very unique position, because you’re going to see a lot of announcements of projects that were put on hold or delayed, or new projects that are coming together, because everybody has been prepping and getting stuff together.” Reinventions Daisy Ridley Some familiar faces entered the market fray in new guises. After launching only two months ago, Neon International made its market debut with an impressive slate under the watch of Kristen Figeroid. Among first projects are It Follows sequel They Follow and Daisy Ridley survival thriller We Bury The Dead. Former Lionsgate UK chief and Marv executive Zygi Kamasa launched UK distributor True Brit Entertainment. Range continues to ramp up its sales involvement under the guidance of Jess Lacy. German outfit K5, which re-launched at Cannes, is selling international on Costner’s Horizon movies. Meanwhile, old war horse Miramax was at its first market in years without figurehead Bill Block so will likely be in the market for a sales and production leader. Going Global Mainstream U.S. distributors and sellers are tapping into international content beyond the traditional European base. On the eve of AFM we broke news of Lionsgate’s deal for Indian action movie, Kill, which is being sold by WME Independent. The rare deal marks one of the first times an Indian production has partnered with a Hollywood studio on a theatrical release in North America and the UK for a mainstream Hindi-language film. It’s also a sign of the times: content is increasingly borderless and companies are increasingly language agnostic. Stuart Ford’s AGC International announced during the AFM that it was handling global rights outside the Middle East and Pakistan to Voy! Voy! Voy!, the dramedy about a group of impoverished Egyptians who join a professional blind soccer team as a ploy to get to Europe. The film is Egypt’s candidate for the international film Oscar. AGC has corporate ties to the film’s financier Image Nation Abu Dhabi and the deal for Voy! Voy! Voy! marks the latest bid to bring Arabic-language content to wider audiences, following their collaboration as co-producers and distributors on action film The Ambush (Al Kameen), directed by Pierre Morel, which is touted as one of biggest Arabic-language features ever shot in the Gulf. Meanwhile, France’s Other Angle Pictures has expanded its footprint into the U.S. market with a new LA-based arm focused on distribution, production and international sales of French features with a focus on crowd-pleasing comedies and more commercial dramas. The global audience for global content continues to grow. Theatrical Promise Theatrical remains a conundrum for the indie market, but also the golden ticket at a time when streamers may be retrenching. The theatrical success of movies like Barbie, Oppenheimer and Five Nights At Freddy’s has breathed life into the theatrical business in recent months. While those three movies are all studio releases, their outsized successes are examples of theatrical’s ongoing promise. For international buyers, finding that unique proposition — an affordable project with strong story, talent, and domestic distribution chances — in the saturated indie markets remains a challenge. Genre offers the potential for that affordable breakout winner and we saw plenty of genre fare on sale in Santa Monica, even if the depth of theatrical product is less than at Cannes. Heading into the market, we also revealed the solid theatrical-level deals done on Guy Ritchie’s new action movie with Jake Gyllenhaal and Henry Cavill . (L-R) Foxy, Chica, Freddy Fazbear and Bonnie in ‘Five Nights at Freddy’s’
Delfina Frequently Asked Questions (FAQ)
When was Delfina founded?
Delfina was founded in 2020.
Where is Delfina's headquarters?
Delfina's headquarters is located at 2021 Fillmore Street, San Francisco.
What is Delfina's latest funding round?
Delfina's latest funding round is Seed - II.
How much did Delfina raise?
Delfina raised a total of $5.97M.
Who are the investors of Delfina?
Investors of Delfina include UnitedHealthcare Accelerator, Mayo Clinic Platform Accelerate, Ellen Pao, E14 Fund, SpringTime Ventures and 10 more.
Who are Delfina's competitors?
Competitors of Delfina include Pomelo Care and 1 more.
What products does Delfina offer?
Delfina's products include Delfina Care.
Who are Delfina's customers?
Customers of Delfina include A&A Women’s Health and Center for Women’s Health.
Compare Delfina to Competitors
Wildflower Health is a technology and services company focused on transforming care delivery and payment models in women's health. The company offers a modular suite of software, support, and services, including digital tools and human touch, to improve healthcare outcomes, particularly in the area of maternity care. Wildflower Health primarily serves patients, healthcare providers, and payers, with a special focus on value-based maternity care. It was founded in 2012 and is based in Cotati, California.
Maven operates as a digital health clinic for women. It offers a mobile application providing users access to instant video appointments and private messaging with healthcare practitioners. It provides solutions from preconception support to fertility preservation, in vitro fertilization (IVF), adoption, surrogacy, and more. The company was founded in 2014 and is based in New York.
Mahmee provides maternal and infant health services. The company offers medical profiling, parental and postpartum health monitoring, care coordination support, and more. It was founded in 2014 and is based in Los Angeles, California.
ProgenyHealth is a healthcare company that focuses on maternity and neonatal intensive care unit (NICU) care management. The company offers services that include integrated maternity and NICU care management, payment validation, and addressing social determinants of health. Its primary customers are health plans, employers, and providers. It is based in Plymouth Meeting, Pennsylvania.
Cleo provides an end-to-end support to working families. It facilitates planning a family to caring for an adult loved one. It offers certified care practitioners who guide and provide advice to parents on parenthood, pregnancy, and more. It provides an application for parents that includes coaching, content, and community with a network of certified experts to guide families through their journey into parenthood and back to work again. It was formerly known as Lucy. The company was founded in 2016 and is based in San Francisco, California.
Rimidi is a healthcare technology company that focuses on chronic disease management and remote patient monitoring. The company offers a clinical management platform that combines patient-generated health data with clinical data to provide patient-specific insights and actions. This platform supports a broad range of clinical use cases, including diabetes, heart failure, cardiovascular disease, fatty liver disease, respiratory diseases, and obesity. Rimidi was formerly known as Rimidi Diabetes Inc.. It was founded in 2012 and is based in Atlanta, Georgia.